Volume 11, Issue 3 (Vol.11 No.3 Oct 2022)                   rbmb.net 2022, 11(3): 421-429 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Yousif Hussin Alimam H, Abdelateif Hussein W, Ibrahim S, Abdelgani S, Alharthi N, Bashier Eltayeb L, et al . Blood Glucose, HbA1c Level, and its Correlation with VEGF-A (+405G/C) Polymorphism as Biomarker Predicts the Risk of Retinopathy and Nephropathy in Type 2 Diabetic Patients. rbmb.net 2022; 11 (3) :421-429
URL: http://rbmb.net/article-1-915-en.html
Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam Bin Abdul-Aziz University, Al Khari- Riyadh, KSA.
Abstract:   (370 Views)
Background: Diabetes-related vascular complications linked to increase in the expression of VEGF and its receptors. It helps to accelerate tissue damage inflicted by hyperglycemia, which is potential risk for diabetic complications. The study aimed to assess VEGF genetic polymorphism and its correlation with glucose and HbA1C level among Sudanese patients with diabetic retinopathy and nephropathy.

Methods: A case-control study was conducted among a total of 252 subjects and divided into four groups of 63 subjects each. Glucose and HBA1c were measured then the VEGF gene was amplified using polymerase chain reaction. The data were analyzed using SPSS.

Results: The HBA1c, and blood glucose levels had significantly (P value≤0.00001) highest mean in the DR group, DN group followed by DM. There is a non-significant correlation between VEGF Genotypes and HbA1c, and blood glucose levels (P value≤0.102, 0.173) Patients with GC genotypes will be 74.6%, and 54% higher at risk to develop DR, and DN respectively and 40 % lower at risk to develop DM than those without GC genotype. While patients with CC genotypes will be 22.2% higher at risk of developing DM and 9.5%, 12.2% higher at risk of developing DR and DN respectively.

Conclusions: The VEGF +405G/C gene polymorphism is linked to diabetic retinopathy, and diabetic nephropathy in type 2 Sudanese diabetics, and the presence of the GC genotypes and G allele is a significant predictor for retinopathy. There is no significant relation between HbA1C serum levels, blood glucose, and the VEGF +405G/C gene polymorphism.
Full-Text [PDF 819 kb]   (131 Downloads)    
Type of Article: Original Article | Subject: Biochemistry
Received: 2022/04/13 | Accepted: 2022/04/24 | Published: 2022/12/31

References
1. Amin N. An Overview of Diabetes Mellitus; Types, Complications, and Management. International Journal of Nursing Science Practice and Research. 2018; 4(1):119-24.
2. Hidayat R, Wulandari P. Effects of Andrographis paniculata (Burm. F.) Extract on Diabetic Nephropathy in Rats. Rep Biochem Mol Biol. 2021;10(3):445-454. [DOI:10.52547/rbmb.10.3.445] [PMID] [PMCID]
3. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. [DOI:10.1016/j.diabres.2019.107843] [PMID]
4. Boutayeb A, Lamlili ME, Boutayeb W, Maamri A, Ziyyat A, Ramdani N. The rise of diabetes prevalence in the Arab region. Open Journal of Epidemiology. 2012;2, 55-60. [DOI:10.4236/ojepi.2012.22009]
5. Boutayeb W, Lamlili ME, Boutayeb A, Boutayeb S. Estimation of the direct cost of diabetes in the Arab region. Mediterranean Journal of Nutrition and Metabolism. 2013; 7(6):732-38. [DOI:10.4236/jbise.2013.67090]
6. Mahdy RA, Nada WM, Hadhoud KM, El-Tarhony SA. The role of vascular endothelial growth factor in the progression of diabetic vascular complications. Eye (Lond). 2010;24(10):1576-84. [DOI:10.1038/eye.2010.86] [PMID]
7. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 2001;280(6):C1358-66. [DOI:10.1152/ajpcell.2001.280.6.C1358] [PMID]
8. Khan MM, Manzoor Sh, Khalid MA, Tarrar MG, Aslam F, Ahmed SI. Factors Responsible for Delay in Initiation of Insulin Treatment in Type-2 Diabetes Mellitus Patients with Secondary Failure of Oral Hypoglycemic Agents. JRMC. 2016; 20(4):244-50.
9. Awuchi CG, Echeta CK, Igwe VS. Diabetes and the Nutrition and Diets for Its Prevention and Treatment: A Systematic Review and Dietetic Perspective. Health Sciences Research. 2020;6(1):5-19.
10. Hussin HY, Hussein WA, Ibrahim AES, Kambal S, Almhdi SA, Abdrabo AEA. Association of Vascular Endothelial Growth Factor +405G/C Polymorphism with Diabetic Retinopathy among Sudanese Patients. Am J Biomed Sci & Res. 2021;11(5):437-443. [DOI:10.34297/AJBSR.2021.11.001675]
11. Mobasher MA, El-Tantawi HG, El-Said KS. Metformin Ameliorates Oxidative Stress Induced by Diabetes Mellitus and Hepatocellular Carcinoma in Rats. Rep Biochem Mol Biol. 2020;9(1):115-128. [DOI:10.29252/rbmb.9.1.115] [PMID] [PMCID]
12. Palmer BF, Clegg DJ. Oxygen sensing and metabolic homeostasis. Mol Cell Endocrinol. 2014 Nov;397(1-2):51-8. [DOI:10.1016/j.mce.2014.08.001] [PMID]
13. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiological reviews. 2013; 93(1):137-88. [DOI:10.1152/physrev.00045.2011] [PMID]
14. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes. 2002;51(10):3090-4. [DOI:10.2337/diabetes.51.10.3090] [PMID]
15. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes. 2004;53(3):861-4. [DOI:10.2337/diabetes.53.3.861] [PMID]
16. Szaflik JP, Wysocki T, Kowalski M, Majsterek I, Borucka AI, Blasiak J, et al. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology. 2008; 246(1):39-43. [DOI:10.1007/s00417-007-0674-6] [PMID]
17. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12(8):1232-5. [DOI:10.1006/cyto.2000.0692] [PMID]
18. Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I, Jozwiak L. Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. Nephrology dialysis transplantation. 2007; 22(3):827-32. [DOI:10.1093/ndt/gfl641] [PMID]
19. Amer AK, Khalaf NA, Aboelmakarem SH, Elsobky MS, Abdelrasoul MR, Abdelazeem AA, et al. Vascular endothelial growth factor+ 405G/C polymorphism as a predictor of diabetic retinopathy. Bull Natl Res Cent. 2020; 44:1-9. [DOI:10.1186/s42269-020-00287-y]
20. Fan X, Wu Q, Li Y, Hao Y, Ning N, Kang Z, et al. Association of polymorphisms in the vascular endothelial growth factor gene and its serum levels with diabetic retinopathy in Chinese patients with type 2 diabetes: a cross-sectional study. Chin Med J (Engl). 2014; 127(4):651-7.
21. Gupta N, Mansoor S, Sharma A, Sapkal A, Sheth J, Falatoonzadeh P, et al. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013; 7: 4-10. [DOI:10.2174/1874364101307010004] [PMID] [PMCID]
22. Wykoff CC, Chakravarthy U, Campochiaro PA, Bailey C, Green K, Cunha-Vaz J. Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy. Ophthalmology. 2017; 124(4):440-9. [DOI:10.1016/j.ophtha.2016.11.034] [PMID]
23. Zhao Y, Singh RP. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. Drugs Context. 2018;7:212532. [DOI:10.7573/dic.212532] [PMID] [PMCID]
24. Tufro A, Veron D. VEGF and podocytes in diabetic nephropathy. Semin Nephrol. 2012;32(4):385-93. [DOI:10.1016/j.semnephrol.2012.06.010] [PMID] [PMCID]
25. Kowalski J, Sliwczyńska-Rodziewicz D, Kowalczyk E, Ciećwierz J, Irzmański R, Pawlicki L, Mejer A, Barylski M. Plasma nitric oxide and vascular endothelial growth factor levels in patients with metabolic syndrome and co-existing vascular complications. Pol Merkur Lekarski. 2011 Apr;30(178):249-52.
26. Garg S, Davis RM. Diabetic retinopathy screening update. Clinical diabetes. 2009; 27(4):140-5. [DOI:10.2337/diaclin.27.4.140]
27. Mitchell P, Wong TY. DIRECT new treatments for diabetic retinopathy. The Lancet. 2008;372(9647):1361-3. [DOI:10.1016/S0140-6736(08)61413-0] [PMID]
28. Jebinth B. A study on the relationship between blood levels of vascular endothelial growth factor and severity of diabetic retinopathy. 2016; http://repository-tnmgrmu.ac.in/id/eprint/2427.
29. Jeganathan VS. Anti-angiogenesis drugs in diabetic retinopathy. Curr Pharm Biotechnol. 2011;12(3):369-72. [DOI:10.2174/138920111794480525] [PMID]
30. Balasubramanyam M, Rema M, Premanand C. Biochemical and molecular mechanisms of diabetic retinopathy. Current Science. 2002; 83(12)1506-14.
31. Yannuzzi LA, Negrão S, Tomohiro I, Carvalho C, Rodriguez- Coleman H, Slakter J, et al. Retinal angiomatous proliferation in age- related macular degeneration. Retina. 2012; 21(5):416-34. https://doi.org/10.1097/IAE.0b013e31823f9b3b [DOI:10.1097/00006982-200110000-00003] [PMID]
32. Penn J, Madan A, Caldwell RB, Bartoli M, Caldwell R, Hartnett M. Vascular endothelial growth factor in eye disease. Progress in retinal and eye research. 2008; 27(4):331-71. [DOI:10.1016/j.preteyeres.2008.05.001] [PMID] [PMCID]
33. Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19(12):1584-96. [DOI:10.1038/nm.3407] [PMID] [PMCID]
34. Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol. 2007; 292(6): F1665-72. [DOI:10.1152/ajprenal.00495.2006] [PMID]
35. Nakagawa T, Sato W, Sautin YY, Glushakova O, Croker B, Atkinson MA, et al. Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy. J Am Soc Nephrol.2006; 17(3):736-45. [DOI:10.1681/ASN.2005070759] [PMID]
36. Zakareia FA, Alderees AA, Al Regaiy KA, Alrouq FA. Correlation of electroretinography b-wave absolute latency, plasma levels of human basic fibroblast growth factor, vascular endothelial growth factor, soluble fatty acid synthase, and adrenomedullin in diabetic retinopathy. Journal of Diabetes and its Complications. 2010; 24(3):179-85. [DOI:10.1016/j.jdiacomp.2008.12.007] [PMID]
37. Yannuzzi LA, Negrão S, Tomohiro I, Carvalho C, Rodriguez- Coleman H, Slakter J, et al. Retinal angiomatous proliferation in age- related macular degeneration. Retina. 2012; 32:416-34. [DOI:10.1097/IAE.0b013e31823f9b3b] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb